The Pharmaceutical Market: Netherlands

Date: January 31, 2013
Pages: 89
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PA11CBEF53DEN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Netherlands
OVERVIEW OF THE PHARMACEUTICAL MARKET IN THE NETHERLANDS

While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands enters a period of slower economic growth. In fact, as we warned , the Dutch authorities recently introduced a new scheme - reimbursement for medicines that prove therapeutically ineffective will be reclaimed from the manufacturer - to reduce public healthcare costs. BMI notes that the 'no cure, no pay' scheme implemented by the Dutch government is not a new concept , with t he US government and a number of Western European governments already having made risk - sharing or money-back guarantee agreements with drug companies. However, these agreements focused on particular medicines, unlike the much harsher 'blanket' stance of the Dutch health ministry.

Headline Expenditure Projections

Pharmaceuticals: EUR6.70bn (US$9.31bn) in 2011 to EUR6.51bn (US$8.27bn) in 2012; -2.8% in local currency terms and -11.2% in US dollar terms. Forecast unchanged from Q4 12.

Healthcare: EUR62.94bn (US$87.49bn) in 2011 to EUR64.43bn (US$81.83bn) in 2012; +2.4% in local currency terms and -6.5% in US dollar terms. Forecast unchanged from Q4 12.

Medical Devices: EUR11.41bn (US$15.86bn) in 2011 to EUR11.72bn (US$14.89bn) in 2012; +2.8% in local currency terms and -6.1% in US dollar terms. Forecast unchanged from Q4 12.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Netherlands Pharmaceuticals And Healthcare Industry SWOT
    Netherlands Political SWOT
    Netherlands Economic SWOT
    Netherlands Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q113
    Rewards
    Risks

THE NETHERLANDS – MARKET SUMMARY

REGULATORY REGIME

    Regulatory Developments
    Intellectual Property Regime
    Pricing Regime
    Reimbursement Regime
    Recent Pricing And Reimbursement Developments

INDUSTRY DEVELOPMENTS

    Epidemiology
    Non-Communicable Diseases
    Healthcare Sector
    Healthcare Funding
    Health Insurance
    Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
    Health Insurance Companies
    Healthcare Insurance Developments
    Table: Biosimilars Approved In The EU
    Research And Development Sector
    Clinical Trials
    Medical Devices Industry
    Medical Devices Industry Developments

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales Indicators, 2008-2016
    Healthcare Market Forecast
    Table: Healthcare Expenditure Indicators, 2008-2016
    Table: Healthcare Governmental Indicators, 2008-2016
    Table: Healthcare Private Indicators, 2008-2016
  Key Growth Factors – Macroeconomic
    Table: Netherlands – Economic Activity
    Prescription Drug Market Forecast
    Table: Prescription Drug Sales Indicators, 2008-2016
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators, 2008-2016
  Generic Drug Market Forecast
  Netherlands Pharmaceuticals & Healthcare Report Q1 2013
      Table: Generic Drug Sales Indicators, 2008-2016
      OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators, 2008-2016
      Table: OTC Medicine Sales Indicators By Category, 2008-2010
      Pharmaceutical Trade Forecast
      Table: Exports And Imports Indicators, 2008-2016
  Medical Devices Market Forecast
      Table: Medical Devices Sales Indicators, 2008-2016
      Other Healthcare Data
      Table: Number Of Physicians By Type, 2008-2009
      Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Pharmaceutical Production, 1995-2010 (Euros 000s)
      Company Activities
      Pharmaceutical Wholesale Sector
      Pharmaceutical Retail Sector

COMPANY PROFILES

  Local Manufacturers
      DSM
      Qiagen
      Pharming Group
  Multinational Manufacturers
      Merck & Co
      Pfizer
      GlaxoSmithKline
      Sanofi
      Novartis

DEMOGRAPHIC DATA

      NETHERLANDS – Population By Age Group
      NETHERLANDS – Population By Age Group
      NETHERLANDS – Key Population Ratios
      NETHERLANDS – Rural and Urban Population

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts
      Pharmaceuticals Business Environment Ratings
      Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceutical Business Environment Indicators
      Weighting
      Table: Weighting Of Components
      Sources
Skip to top


The Pharmaceutical Market: Italy US$ 1,295.00 Jan, 2013 · 76 pages
The Pharmaceutical Market: Japan US$ 1,295.00 Jan, 2013 · 99 pages
The Pharmaceutical Market: Jordan US$ 1,295.00 Jan, 2013 · 112 pages

Ask Your Question

The Pharmaceutical Market: Netherlands
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: